©The Author(s) 2016.
World J Gastrointest Oncol. Mar 15, 2016; 8(3): 248-257
Published online Mar 15, 2016. doi: 10.4251/wjgo.v8.i3.248
Published online Mar 15, 2016. doi: 10.4251/wjgo.v8.i3.248
Table 4 Ongoing neoadjuvant/borderline resectable trials
| Trial | Registration No. | Treatment groups | Primary endpoint | Patients planned |
| NEONAX | NCT02047513 | 2 cycles Gem + nab-paclitaxel neoadjuvant | DFS | 166 |
| 4 cycles Gem + nab-paclitaxel adjuvant | ||||
| 6 cycles Gem + nab-paclitaxel adjuvant | ||||
| Perioperative mFOLFIRINOX | NCT02047474 | 3 cycles FOLFORINOX | DFS | 46 |
| Neoadjuvant + adjuvant | ||||
| NEOLAP | NCT02125136 | 2 cycles Gem + nab-paclitaxel | Conversion rate | 168 |
| + 2 × FOLFIRINOX | (including locally advanced PDAC) | |||
| + adjuvant 3 × Gem + nab-paclitaxel | ||||
| 4 cycles Gem + nab-paclitaxel | ||||
| + adjuvant 3 × Gem + nab-paclitaxel |
- Citation: Sinn M, Bahra M, Denecke T, Travis S, Pelzer U, Riess H. Perioperative treatment options in resectable pancreatic cancer - how to improve long-term survival. World J Gastrointest Oncol 2016; 8(3): 248-257
- URL: https://www.wjgnet.com/1948-5204/full/v8/i3/248.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v8.i3.248